Clinical trials: Binge Eating Disorder (BED)

Binge Eating Disorder

Open Label Extension in Adults With Binge Eating Disorder (BED)

• Completed
• Age: 18 to 55 years
• Phase 3
• Results posted

To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults

Trial name

NCT01657019

Testing

Lisdexamfetamine dimesylate

Where

89 sites in United States, Germany and 1 more

Volunteers

604 people

Sponsor

Shire